

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/266203 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) *C12N 5/10* (2006.01)
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2022/033598

(22) International Filing Date:

15 June 2022 (15.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/210,979 15 June 2021 (15.06.2021) US
63/351,223 10 June 2022 (10.06.2022) US

(71) Applicant: **ALLOGENE THERAPEUTICS, INC.**
[US/US]; 210 East Grand Avenue, South San Francisco,
California 94080 (US).

(72) Inventors: **LAURON, Elvin J.**; c/o Allogene Therapeutics,
Inc., 210 E. Grand Avenue, South San Francisco, Califor-
nia 94080 (US). **PANOWSKI, Siler**; c/o Allogene Thera-
peutics, Inc., 210 E. Grand Avenue, South San Francisco,
California 94080 (US). **SASU, Barbra Johnson**; c/o Allo-
gene Therapeutics, Inc., 210 E. Grand Avenue, South San
Francisco, California 94080 (US). **SOMMER, Cesar Adol-
fo**; c/o Allogene Therapeutics, Inc., 210 E. Grand Avenue,
South San Francisco, California 94080 (US). **SRIVATSA
SRINIVASAN, Surabhi**; c/o Allogene Therapeutics, Inc.,
210 E. Grand Avenue, South San Francisco, California
94080 (US). **VAN BLARCOM, Thomas John**; c/o Allo-
gene Therapeutics, Inc., 210 E. Grand Avenue, South San
Francisco, California 94080 (US). **LANG, Shanshan**; c/o
Allogene Therapeutics, Inc., 210 E. Grand Avenue, South
San Francisco, California 94080 (US).

(74) Agent: **CHANG, Y. Elaine** et al.; Allogene Therapeutics,
INC., Legal IP, 210 East Grand Avenue, South San Fran-
cisco, California 94080 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) Title: SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE

(57) Abstract: Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engi-
neered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are en-
gineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and
hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule
e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer
or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more
of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising
them, and methods of treating by administering them.



WO 2022/266203 A1